FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug

Neurocrine Biosciences, Inc. NBIX announced that the FDA has accepted its new drug application (NDA) for opicapone as an adjunct therapy to levodopa/carbidopa to treat patients with Parkinson's disease (PD), who are experiencing OFF episodes.